NCT04975997: EXCALIBER-RRMM

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Active, enrolled Phase 3 Last updated 3 April 2026

What this trial tests

Phase 3 trial testing Dexamethasone in Multiple Myeloma in 939 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

23 June 2022

Primary endpoint
16 November 2027

25 June 2032

Quick facts

Lead sponsor	Celgene
Phase	Phase 3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	939
Start date	23 June 2022
Primary completion	16 November 2027
Estimated completion	25 June 2032
Sites	259 locations across Italy, Finland, Japan, Taiwan, Ireland, Poland, South Korea, Denmark

Drugs / interventions tested

• Dexamethasone (dexamethasone) — full drug profile →
• Daratumumab (daratumumab) — full drug profile →
• Bortezomib (bortezomib) — full drug profile →
• Iberdomide
• Iberdomide
• Iberdomide
• Dexamethasone (dexamethasone) — full drug profile →
• Daratumumab (daratumumab) — full drug profile →

Conditions studied

• Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Celgene — full company profile →

Who can join

18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Targeted protein degradation: advances in drug discovery and clinical practice.
   Zhong G, Chang X, Xie W, Zhou X. · · 2024 · cited 112× · PMID 39500878 · DOI 10.1038/s41392-024-02004-x
2. The emerging therapeutic landscape of relapsed/refractory multiple myeloma.
   Tanenbaum B, Miett T, Patel SA. · · 2023 · cited 46× · PMID 36462062 · DOI 10.1007/s00277-022-05058-5
3. Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond.
   Podar K, Leleu X. · · 2021 · cited 42× · PMID 34680303 · DOI 10.3390/cancers13205154
4. Novel approaches to targeted protein degradation technologies in drug discovery.
   Xue Y, Bolinger AA, Zhou J. · · 2023 · cited 34× · PMID 36895136 · DOI 10.1080/17460441.2023.2187777
5. Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies.
   Wu HT, Zhao XY. · · 2022 · cited 21× · PMID 35342342 · DOI 10.7150/ijbs.68148
6. RIPTACs: A groundbreaking approach to drug discovery.
   Ma Z, Bolinger AA, Zhou J. · · 2023 · cited 20× · PMID 37734702 · DOI 10.1016/j.drudis.2023.103774
7. Targeted Protein Degradation: Clinical Advances in the Field of Oncology.
   Salama AKAA, Trkulja MV, Casanova E, Uras IZ. · · 2022 · cited 19× · PMID 36499765 · DOI 10.3390/ijms232315440
8. Immunometabolism: signaling pathways, homeostasis, and therapeutic targets.
   Xu R, He X, Xu J, Yu G, et al · · 2024 · cited 18× · PMID 39492834 · DOI 10.1002/mco2.789